Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab

Table 1 Baseline demographics of patients with treatment-resistant nAMD switched to faricimab

Number of patients	41
Number of eyes	46
Mean age (years)	74.70 ± 7.04
Gender
Male	15
Female	26
Mean prior anti-VEGF injections
Total (n)	30.22 ± 25.51
Total RBZ	12.26 ± 12.80
Total AFL	19.30 ± 19.71
Mean injections per year	8.50 ± 3.06
Last injection
RBZ	10
AFL	36
CNV type
I	19
II	18
III	9
Mean Faricimab injections during study	7.43 ± 0.78

This table summarizes the baseline characteristics of 41 patients (46 eyes) included in the study. Key demographic information includes age, gender distribution, and choroidal neovascularization (CNV) type. The history of prior anti-VEGF treatment is detailed, including the number of total intravitreal injections (RBZ: ranibizumab; AFL: aflibercept), mean injections per year, and the last anti-VEGF agent administered before the switch to Faricimab. Moreover, the mean number of Faricimab injections per patient during the study period is shown

ISSN: 2056-9920